Character Biosciences
Character Biosciences develops targeted therapies by identifying the genetic and molecular drivers of progressive polygenic diseases such as age-related macular degeneration. The company combines human genomics with longitudinal clinical records, retinal imaging, AI-enabled biomarker quantification, and machine learning to reclassify disease into genetically defined subtypes and pinpoint therapeutic targets. Character Bio operates as a precision medicine drug-discovery and development company that partners with ophthalmology clinics to build deeply phenotyped patient cohorts for research and trial enrollment. Its platform supports target discovery, patient selection, and the advancement of lead programs toward clinical trials. The approach aims to deliver more precise medicines by matching individual patients to therapies that address their specific disease drivers.
Character Biosciences
Character Biosciences develops targeted therapies by identifying the genetic and molecular drivers of progressive polygenic diseases such as age-related macular degeneration. The company combines human genomics with longitudinal clinical records, retinal imaging, AI-enabled biomarker quantification, and machine learning to reclassify disease into genetically defined subtypes and pinpoint therapeutic targets. Character Bio operates as a precision medicine drug-discovery and development company that partners with ophthalmology clinics to build deeply phenotyped patient cohorts for research and trial enrollment. Its platform supports target discovery, patient selection, and the advancement of lead programs toward clinical trials. The approach aims to deliver more precise medicines by matching individual patients to therapies that address their specific disease drivers.